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Abstract
Objectives:
Interleukin-10 (IL-10) downregulates T cell-mediated immune responses. We studied the
association between IL-10 production by freshly isolated melanoma cell suspensions in
vitro and overall survival in patients undergoing adjuvant treatment with a vaccine
prepared from the same autologous melanoma cells modified with a hapten, dinitrophenyl
(DNP).
Methods:
Forty-four patients with cutaneous melanoma (29 stage III and 15 stage IV) were
prospectively evaluated. Tumor cells were extracted from metastatic deposits for
production of DNP-modified autologous melanoma cell vaccine. Small aliquots of the
melanoma cell suspensions were separated prior to vaccine processing and cultured
overnight for IL-10 production. Based on a blind assessment of the distribution of IL-10
levels in the culture supernatants, a cut-off of 200 pg/ml was used to define high versus
low IL-10 producers. Cox regression model was used for multivariate analysis. Overall
survival was calculated using the Kaplan-Meier method and survival curves were
compared with the log-rank test.
Results:
Out of 44 patients, 29 were low and 15 were high IL-10 producers. The median OS was
significantly worse for high compared to low IL-10 producers (10.5 months v 42 months;
P=0.022). In stage III patients, the multivariate hazard ratio for high versus low IL-10
producers was 2.92 (95% CI, 1.04-8.20; P=0.041). The corresponding hazard ratio in
stage IV patients was 0.92 (95% CI, 1.04-8.20; P=0.888).
Conclusions:
High IL-10 production in the tumor microenvironment could be a determinant of clinical
outcomes in stage III melanoma patients receiving autologous melanoma cell vaccine.
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Introduction
The cytokines produced in the tumor microenvironment are key factors in modulating an
anti-tumor immune response induced by active specific immunotherapies such as a
cancer vaccine. We have reported that mRNA of interleukin 10 (IL-10) was present in
metastatic melanoma tissues and IL-10 was produced by melanoma cells freshly isolated
from metastases [1]. Furthermore, serum IL-10 levels correlated to disease progression of
patients with metastatic melanoma [1-3].
Elevated IL-10 expression has been demonstrated in various human tumors
including melanoma, ovarian cancer, head and neck cancer, renal cell carcinoma, colon
cancer, lymphoma and myeloma [1, 4-12]. Elevated serum IL-10 levels have been
reported as a negative prognostic factor in Hodgkin and non-Hodgkin lymphomas [13,
14]. Detectable serum levels of IL-10 have also been demonstrated to be associated with
poor clinical outcomes in other tumors including hepatocellular cancer, renal carcinoma,
lung cancer, gastric, and colorectal carcinoma [15-18]. Preclinical data suggests that IL10 in the tumor microenvironment plays a critical role in tumor progression and
metastases [8].
In this study, we investigated the correlation between the clinical outcomes of
melanoma patients treated with autologous cancer vaccine and the IL-10 levels in their
tumor specimens used for cancer vaccine production. We hypothesized that the
production of IL-10 by melanoma cell suspensions used for cancer vaccine would reflect
the IL-10 levels in the tumor microenvironment [1, 5]. We further hypothesized that high
IL-10 production in the tumor microenvironment is detrimental to the efficacy of cancer
vaccine.

Materials and Methods
Patients
The study population consisted of 44 consecutive melanoma patients who
received an autologous DNP-modified melanoma cell vaccine between October 1995 and
April 1996. After the surgical resection of their metastasis, all patients received a vaccine
consisting of autologous melanoma cells modified with a hapten, dinitrophenyl (DNP).
The DNP-modified melanoma cell cancer vaccine study was approved by Institutional
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Review Board at Thomas Jefferson University. Informed consent was obtained from all
the patients participating in the study. Patients were entered onto the protocol within 30
days of surgical removal of their metastasis. The major entry criteria were as follows:
sufficient amount of tumor specimens for vaccine processing (≥ 2.5 cm); excellent
performance statues (Karnofsky score ≥70); age ≥ 16 years; no systemic anti-melanoma
therapy within 8 weeks of study entry; and not taking corticosteroids or other
immunosuppressive drugs.

Cancer vaccine preparation and treatment
The method of preparing autologous, DNP-modified vaccine and the schedule of
administration of vaccine have been previously described [19, 20]. In brief, tumor cells
were extracted by enzymatic dissociation of freshly obtained metastatic melanoma with
collagenase and DNAase, aliquoted, frozen in a controlled-rate freezer, and stored in
liquid nitrogen in a medium containing 2.5% human albumin and 10% dimethylsulfoxide
until needed. On the day of treatment, an aliquot of tumor cells was thawed. Small
sample of tumor cells was separated, cultured overnight and then assayed for the presence
of IL-10 in the culture supernatants. The rest of the cells for vaccine production were
washed, and irradiated to 25 Gy. Then the cells were washed again and modified with
DNP. This involved a 30-minute incubation of tumor cells with dinitrofluorobenzene
(DNFB), followed by washing with saline. Each vaccine fell within a specified dose
range of live (trypan blue–excluding) tumor cells suspended in 0.2 mL of Hanks solution
with human serum albumin. The final (haptenized) vaccine product (2.5-7.5 x 106 cells)
did not produce any IL-10. Cyclophosphamide 300 mg/m2 was administered 3 days prior
to the first vaccine injection. The vaccine product was mixed with a titrated dose of
Bacille Calmette-Guérin (BCG), and injected intra-dermally on a weekly basis for 6
times. A booster vaccine was given at 6 months if patients had no sign of recurrence.
After the completion of 6 weekly vaccine treatments, patients were evaluated by history
and physical examination every 2 months in years 1 and 2, every 3 months in year 3,
every 6 months in years 4 and 5 and yearly thereafter. All patients were followed for a
minimum of 5 years or until death. Overall survival (OS) of individual patient was
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measured from the date of surgery to their death or last date of follow up. Patients who
were alive at the time of analysis or lost to follow-up were censored.

Delayed type hypersensitivity (DTH) response to melanoma cells
Prior to and after completion of 6 weekly vaccines, patients were tested for DTH
to modified and unmodified vaccine consisting of autologous melanoma cells. Skin test
materials were injected intradermally into the ventral forearm. After 48 hours the
maximum diameter of skin induration was measured. A positive response was defined as
a maximum diameter of induration ≥ 5 mm.

Measurement of IL-10 levels
For IL-10 production, tumor-derived cells were counted under microscope and
cell numbers were adjusted to l06 live tumor cells/ml based on size and morphology of
cells and exclusion of dead cells by trypan blue. Two hundred microliter of tumor cell
suspensions (2 x 105 tumor cells) were placed in triplicate in a 96 flat-bottomed microtiter
plate in RPMI (Mediatech, Washington, DC) supplemented with 10% fecal calf serum, 4
mM L-glutamine, 10 mM HEPES, 1% non-essential amino acid, penicillin G at 100
U/ml, and streptomycin at 100 µg/ml. Tumor cells were cultured at 37 Co in 5% CO2
incubator over night (18 hours) and supernatants were collected and stored at -20 Co. IL10 levels were measured by commercially available validated ELISA kit for human IL-10
(Endogen, Cambridge, MA). The sensitivity of this assay is 3 pg/ml. There is no crossreactivity of this kit with other human cytokines. The mean of IL-10 levels in triplicate
was used as IL-10 level for each specimen. Standard deviations of the test results in these
triplicates were less than 10% of the means. In patients whose tumor specimens were
tested for IL-10 production on multiple occasions, median IL-10 level was used for study
analysis.

Statistical analysis
All analyses were done using SAS (SAS Institute, Inc., Cary, NC) and S-Plus 8.0
(Insightful Corp., Seattle, WA) statistical software. Descriptive statistics were used to
characterize the study population. The cut-off of 200 pg/ml was used to differentiate high
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versus low IL-10 producers based on the histogram (Figure 1). The histogram of the IL10 levels suggested that the distribution of IL-10 levels in these data may be viewed as a
mixture of two subpopulations with different location and scale parameters, with 200
pg/ml level as an approximate boundary or joint point of the two subpopulations. The
first subpopulation (66% of the data) is more localized and distributed on the interval (0200), while the second subpopulation (34% of the data) has substantially higher spread
over the interval (200-1000). Since the sample size is relatively small, the IL-10 levels
were dichotomized using 200 pg/ml as a cutoff for statistical analysis.
The differences between proportions of patients were tested using Fisher’s exact
test. Univariately, OS was evaluated using Kaplan-Meier survival curves and differences
in survival were tested using the log-rank test. Cox regression model was used to estimate
multivariable-adjusted hazard ratios (HR) and 95% confidence intervals (95% CI). The
final covariates used in the multivariate analysis were IL-10 levels, age, sex, stage and
the interaction term between stage and IL-10 levels. The model incorporated age
(dichotomized as ≥ 60 years v < 60 years) and gender as known prognostic factors.
Proportional hazard assumptions were appropriate overall and for each covariate. The
two sided p-value of 0.05 was used for statistical significance.

Results
The study population consisted of 29 stage III and 15 stage IV cutaneous melanoma
patients treated with an autologous DNP-modified vaccine. The 29 stage III patients had
undergone complete resection of their metastases. Two out of 15 patients with stage IV
melanoma had no clinical evidence of disease after the surgery.
Although single cell melanoma suspensions were made from the same melanoma
metastasis, the production of IL-10 by individual cell suspensions would be variable due
to minor differences in cell preservation condition and process of vaccine production.
Therefore, we tested individual melanoma cell suspensions that were obtained from the
same batch of tumor specimens and used for vaccine production as long as sufficient
aliquots of tumor cells suspensions were available for IL-10 measurement (median of 4
tumor cell suspensions, range 1-5). The median IL-10 level of single cell suspensions
from the same batch of tumor specimens was used for study analysis. Multiple (4 or 5)
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measurements of IL-10 production were available for 34 patients. From the linear mixed
effects model fitted to repeated log transformed IL-10 measures with the random effect of
patient, it was estimated that the mean log transformed IL-10 level was 4.83 (125 on the
original scale), within-patient standard deviation of log transformed IL-10 measures was
0.71, and between-patient standard deviation of log transformed IL-10 measures was
1.27. Thus, the coefficient of variation associated with multiple within-patient measures
is 0.147.
Levels of IL-10 produced by freshly isolated melanoma cell suspensions ranged
from 5.6 pg/ml to 981.3 pg/ml with the median of 154.9 pg/ml and mean of 254.2 pg/ml.
As described in the statistical analysis section, an IL-10 level of 200 pg/ml was taken as a
cutoff to differentiate low and high IL-10 producers. By this definition, 29 patients (66%)
were low IL-10 producers (<200 pg/ml) and 15 patients (34%) were high IL-10 producers
(≥200 pg/ml). The median follow up time was 125 months (10.4 years). Baseline
characteristics of the study population are summarized in Table 1. The differences in the
baseline characteristics were not statistically significant in two groups. Low IL-10
producers had a higher proportion of patients with stage III disease (72% v 53%)
although this is not statistically significant (P=0.315). Additionally, the cohort of IL-10
low producers included more patients with ages older than 60 years, compared to those
with high IL-10 producers (38% v 20%, respectively, P=0.314). The median age of
patients in the low and high IL-10 producers was 55 years (range: 23 to 81 years) and 57
years (range: 34 to 75 years) respectively. Seven patients (24%) in low IL-10 producers
and 2 patients (13%) in high IL-10 producers group had received prior treatment with
chemotherapy, radiation, interferon, immunotherapy or a combination thereof (P=0.695).
In stage III melanoma patients, there were no significant differences among the two
groups with respect to the original site of tumor and nodal status.
The univariate analysis of the potential prognostic variables indicated that the
stage of the disease was the major determinant of survival (Table 2). The median OS of
patients with stage III and stage IV disease was 55.8 months and 12.3 months
respectively (P<0.001). The DTH response to unmodified autologous melanoma cells
was not a significant prognostic determinant of OS, although there is a tendency of better
survival in patients who developed a positive DTH response to melanoma cells after
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vaccine treatments. The levels of tumor-derived IL-10 are also significant prognostic
factor for survival. The median OS was significantly longer for low IL-10 producers as
compared to high IL-10 producers (42 months v 10.5 months, P=0.022). Figures 2 and 3
demonstrate the Kaplan-Meier survival curves stratified by levels of IL-10 in tumor cell
suspensions. It is of note that the impact of tumor-derived IL-10 on survival was more
prominent in stage III patients although the difference was not statistically significant
(median OS for low IL-10 producers and high IL-10 producers was 84 months and 9.7
months respectively; P=0.073). For stage IV patients, there was no significant difference
between low and high IL-10 producers (13.7 months v 10.5 months, P=0.624).
To further investigate the impact of tumor-derived IL-10 on OS, a multivariate
analysis was done using Cox proportional hazard model (Table 3). The univariate
analysis suggested possible association between IL-10 levels and stage. Therefore, the
Cox model incorporated interaction between the stage and IL-10 level. For stage III
patients, the HR for high v low IL-10 producers was 2.92 (95% CI: 1.04-8.20, P=0.041).
In stage IV patients, the corresponding HR of 0.92 (95% CI: 0.28-3.00, P=0.888) was not
statistically significant. Furthermore, the difference in OS between stage III and IV is
only seen in low IL-10 producers. In low IL-10 producers, the HR for stage IV v stage III
was 4.95 (95% CI: 1.74-14.09, P=0.003). In contrast, the corresponding HR for stage IV
v III in high IL-10 producers was 1.56 (95% CI: 0.51-4.81, P=0.440).

Discussion
Therapeutic vaccines for the treatment of cancer aim to induce or boost T-cell immunity
against tumor-specific or tumor-associated antigens. It is the general consensus that
cancer vaccine could elicit a T cell immune response against cancer antigens that were
used for vaccine treatment [21]. However, there is significant discrepancy between
development of systemic immunity against targeted antigens and clinical outcome of
cancer vaccine treatments. Furthermore, the presence of vaccine-elicited cytotoxic T
lymphocytes in tumors expressing the targeted epitope also has been demonstrated
without tumor regression [22]. It has been speculated that the discrepancy between
increased numbers of tumor-specific T cells after cancer vaccine administration and the
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lack of clinical response might be explained by the interaction between cancer cells and
the host immune system at the tumor site. Our current study indicates that tumor-derived
IL-10 might be one of the factors to hamper the efficacy of cancer vaccine.
IL-10 has been proposed to modulate anti-tumor immune response by itself or in
conjunction with other cytokines such as transforming growth factor (TGF)-beta. IL-10 is
known to play a role in down regulating the expression of Th1 cytokines, thus
augmenting the immunosuppressive activity of TGF-beta [23, 24]. IL-10 suppresses the
T-cell immune response against melanoma cells by down regulating expression of MHC
class I, class II and ICAM-1 (RW.ERROR - Unable to find reference:103). IL-10 also
down regulates co-stimulatory molecules such as CD 40 expression on dendritic cells in
tumor microenvironment and suppresses their maturation and functions [25]. Dendritic
cells derived from patients with progressive metastatic melanoma induce anergy in helper
T cells [26]. Overexpression of IL-10 in IL-10 transgenic mice has been demonstrated to
limit the ability of these mice to control the growth of immunogenic tumors [27].
Furthermore, IL-10 has an inhibitory effect on CTLA-4 blockade for tumor-eradicating
immunity. It has been reported that anti-CTLA-4 antibody alone may not provide
therapeutic benefit in patients with a tumor that produces IL-10 [28]. These experiments
support the critical role of IL-10 in the tumor microenvironment in modulating anti-tumor
immune response.
In this study, high IL-10 levels in metastatic melanoma tissues are associated with
poorer survival in stage III melanoma patients treated with DNP-modified autologous
melanoma cell vaccine. However, the association between IL-10 levels and survival was
not seen in stage IV patients. Tumor burden is important in immunotherapy and it is
possible that vaccine itself might not have been effective in stage IV patients who had a
residual clinically detectable tumor. In fact, 87% of stage IV patients had radiologically
or clinically detectable disease after the surgery in this study. Since most patients died
from progression of disease within 2 years, the therapeutic effect of vaccine was likely
modest in stage IV patients. It is also possible that due to fewer number of stage IV
patients in this study, the influence of IL-10 could not be accurately evaluated.
Additionally, the multivariate analysis indicates that difference in survival between stage
III and IV patients treated with DNP-modified autologous melanoma cell vaccine was
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only seen in low IL-10 producers. The better survival in stage III patients, compared to
stage IV patients, was not seen in high IL-10 producers. This observation may suggest the
detrimental effect of IL-10 in stage III patients who were treated with DNP-modified
melanoma cell vaccine. Our study indicates that the tumor-derived IL-10 would affect the
efficacy of autologous melanoma cell vaccine in stage III patients although appropriate
control (patients not receiving vaccine) should be included in a future large-scale clinical
trial to support this conclusion.
The majority of patients in this study had one large tumor (>2.5 cm) removed for
the vaccine production. Furthermore, stage III patients were clinically disease free after
surgical removal of lymph node metastasis; therefore, we were not able to test various
tumor specimens from the same patients. It would be possible that the production of IL10 might be different in tumors in a different location; however, we assume that the
tendency of IL-10 production (high or low) would be most likely similar since they are
synchronous systemic metastases from the same primary cutaneous melanoma.
The ability of IL-10 to suppress antitumor immunity is confounded by
observations indicating that IL-10 may promote antitumor immunity under other
conditions in animal models [26, 29, 30]. Despite conflicting data obtained from
artificially induced IL-10 in mice models, our clinical observations [1] as well as number
of other studies indicate that serum IL-10 levels are correlated with adverse clinical
outcomes in patients with melanoma and other tumors [8, 13-18]. Our current study also
supports the potential detrimental effects of tumor-derived IL-10 on autologous
melanoma cell vaccine.
In summary, we have demonstrated first in human that tumor-derived IL-10
might predict the outcome of autologous cancer vaccine. Our data suggest that the effect
of autologous vaccine in stage III melanoma patients may be enhanced by addition of an
antagonist of IL-10. In fact, we have developed immunoadhesins for IL-10 by combining
the extracellular domain of human IL-10 receptor 1 with the Fc regions of human IgG1
heavy chain [31]. The IL-10 immunoadhesins efficiently block the biologic activity of
human IL-10 produced by melanoma cells in vitro. The IL-10 immunoadhesins can be
administered by either intra-tumorally or systemically to facilitate the induction of antitumor immune response after cancer vaccine. The blocking of IL-10 in tumor
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microenvironment itself may also be a useful therapeutic strategy in melanoma patients.
However, due to the complexity of biological effects of IL-10 in the immune system, this
strategy should be tested in carefully designed preclinical and clinical models.
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Table 1: Baseline characteristics of the patients
Low IL-10 producers High IL-10 producers P-value
Number of patients

29

15

55 (23-81)

57 (34-75)

≥ 60 years

11 (38%)

3 (20%)

< 60 years

18 (62%)

12 (80%)

Male

17 (59%)

10 (67%)

Female

12 (41%)

5 (33%)

III

21 (72%)

8 (53%)

IV

8 (28%)

7 (47%)

7 (24%)

2 (13%)

0.695

≥ 5 mm

15 (52%)

11 (73%)

0.299

< 5 mm

11 (38%)

3 (20%)

Unknown

3 (10%)

1 (7%)

Median age (range), years
Age

0.314

Sex
0.748

Stage

Prior therapy

0.315

DTH response

Abbreviations: DTH, delayed type hypersensitivity
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Table 2: Univariate analysis of effect of variables on OS
Median OS (months)

95% CI

P

≥ 60 years

15.1

10.5 to 84.0

0.663

< 60 years

19.0

9.7 to 56.5

Male

13.6

9.7 to 52.6

Female

20.2

12.3 to NR

III

55.8

13.1 to NR

IV

12.3

7.7 to 17.9

Yes

13.7

4.7 to 18.5

No

20.2

12.3 to 56.5

≥ 5 mm

26.7

13.1 to 84.0

< 5 mm

15.7

7.5 to 55.8

≥ 200 pg/ml

10.5

7.5 to 13.1

< 200 pg/ml

42.0

13.7 to NR

Parameter
Age

Sex
0.169

Stage
<0.001

Prior therapy
0.294

DTH response
0.395

IL-10 levels
0.022

Abbreviations: OS, overall survival; DTH, delayed type hypersensitivity; NR, not
reached
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Table 3. Multivariate analysis of variables
Factor

Hazard Ratio

95% CI

P

Age ≥ 60 years v age < 60 years

1.23

0.54 to 2.83

0.621

Male v female

1.79

0.81 to 3.95

0.151

Stage IV v III in high IL-10

1.56

0.51 to 4.81

0.440

Stage IV v III in low IL-10

4.95

1.74 to 14.09 0.003

High IL-10 v low IL-10 in stage III

2.92

1.04 to 8.20

0.041

High IL-10 v low IL-10 in stage IV

0.92

0.28 to 3.00

0.888
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Figure 1. Production of IL-10 by tumor cell suspensions. The arrow denotes the cutoff
point (IL-10 level of 200 pg/ml) to differentiate low versus high IL-10 producers.
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Figure 2. Overall survival of patients treated with autologous, DNP-modified vaccine
stratified by IL-10 levels.
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Figure 3. Overall survival of melanoma patients stratified by stage and IL-10 levels. The
p-values for the differences in survival among low and high IL-10 producers in stage III
and stage IV patients were 0.073 and 0.624 respectively.
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